A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A SECOND DOSE OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE GIVEN 5 YEARS AFTER THE INITIAL DOSE IN OLDER ADULTS | Arctuva